MIT researchers reported a novel degradable ionizable lipid‑based LNP that delivered an influenza mRNA vaccine in mice at roughly 1/100th the dose of current formulations while maintaining comparable immune responses. The new lipid class, AMG1541, combines cyclic amino alcohol motifs and biodegradable esters to enhance endosomal escape and reduce required payload. The team published results in Nature Nanotechnology and highlighted potential to lower per‑dose cost and reduce reactogenicity for future mRNA vaccines. The approach relied on sequential combinatorial chemistry and in vivo screens to identify top‑performing formulations. While promising preclinically, the formulation requires scale‑up, toxicology, and translational work; nevertheless, the platform could materially affect vaccine economics and expand mRNA applications beyond high‑dose indications.